Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 10/20 | 0.65 |
| ▸ | THRB | P10828 | 10/20 | 0.65 |
| ▸ | RARB | P10826 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | RARA | P10276 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.57 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.54 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31135479 | 1.00 | THRA (0.65) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL31135480 | 1.00 | THRA (0.65) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL31135463 | 0.93 | PLK1 (0.60) | THRATHRBRARBALDH1A1HAO1 | |
| SCHEMBL2853869 | 0.86 | THRA (0.77) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL2849969 | 0.86 | THRA (0.77) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL9383369 | 0.86 | THRA (0.63) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL28137624 | 0.84 | THRA (0.61) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL14660877 | 0.83 | CYP4A11 (0.73) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL10986414 | 0.83 | CYP4A11 (0.73) | THRATHRBRARBMEN1KMT2A | |
| SCHEMBL12814607 | 0.83 | CYP4A11 (0.73) | THRATHRBRARBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070874-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | KJ CHEMICALS CORPORATION (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4610249-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | KJ Chemicals Corporation (JP) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024210074-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | ＫＪケミカルズ株式会社 | 2024-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070874-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | CRYAA, BCAT1, BRCA1 | THRA 888/4885THRB 1653/4885RARB 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.